Search Results - "Cyclophosphamide/adverse effects/therapeutic use"
-
1
Authors:
Contributors:
Subject Terms: AML, acute monoblastic leukemia, isochromosome 5p, clonal evolution, Leukaemia Section, Adult, Aged, Antineoplastic Agents, Alkylating/*adverse effects, Chromosome Aberrations, Chromosomes, Human, Pair 5/genetics, Pair 7/genetics, Cyclophosphamide/adverse effects/therapeutic use, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, In Situ Hybridization, Fluorescence, Leukemia, Myeloid, Acute/*etiology/genetics/mortality/pathology, Male, Melphalan/adverse effects/therapeutic use, Middle Aged, Multiple Myeloma/*drug therapy/genetics, Myelodysplastic Syndromes/*etiology/genetics/mortality/pathology
Relation: Atlas of Genetics and Cytogenetics in Oncology and Haematology; http://AtlasGeneticsOncology.org/Anomalies/i05p10ID1825.html; Adriana, Zamecnikova. i(5)(p10) in hematological malignancies. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, 10, p. 304-306; http://hdl.handle.net/2042/70576; https://doi.org/10.4267/2042/70576
-
2
Authors: et al.
Contributors: et al.
Source: The Journal of Rheumatology. 42:1661-1666
Subject Terms: Male, BLADDER TOXICITY, systemic sclerosis, Follow-Up, retrospective study, PULSE CYCLOPHOSPHAMIDE, Oral Cyclophosphamide, vasculitis, DOUBLE-BLIND, Rheumatic diseases, 0302 clinical medicine, systemic lupus erythematosus, middle aged, Cystitis, 10. No inequality, rheumatic disease, Pulse Cyclophosphamide, Wegeners-Granulomatosis, adult, Incidence, Middle Aged, cohort analysis, Lupus Nephritis, 3. Good health, Bladder Toxicity, aged, female, Treatment Outcome, priority journal, Controlled-Trial, chemically induced, bladder cancer, Female, RHEUMATIC DISEASES, Double-Blind, Adult, Aged, Cyclophosphamide/*adverse effects/therapeutic use, Cystitis/chemically induced/*epidemiology, Humans, Mesna/*therapeutic use, Protective Agents/*therapeutic use, Rheumatic Diseases/*drug therapy, CONTROLLED-TRIAL, Protective Agents, MESNA, Article, INDUCED HEMORRHAGIC CYSTITIS, 03 medical and health sciences, INTRAVENOUS CYCLOPHOSPHAMIDE, WEGENERS-GRANULOMATOSIS, male, Rheumatic Diseases, Induced Hemorrhagic Cystitis, Hemorrhagic cystitis, controlled study, human, cystitis, Cyclophosphamide, ORAL CYCLOPHOSPHAMIDE, protective agent, Mesna, treatment duration, major clinical study, LUPUS NEPHRITIS, HEMORRHAGIC CYSTITIS, Intravenous Cyclophosphamide, treatment outcome, incidence, mesna, cyclophosphamide, hemorrhagic cystitis, FOLLOW-UP
File Description: application/pdf
Access URL: https://www.jrheum.org/content/49/1.toc.pdf
https://pubmed.ncbi.nlm.nih.gov/26178288
https://www.ncbi.nlm.nih.gov/pubmed/26178288
http://openaccess.marmara.edu.tr/handle/11424/89582
https://www.jrheum.org/content/42/9/1661
https://www.jrheum.org/content/jrheum/42/9/1661.full.pdf
https://www.jrheum.org/content/early/2015/07/10/jrheum.150065.abstract
https://pubmed.ncbi.nlm.nih.gov/26178288/
https://avesis.kocaeli.edu.tr/publication/details/96b9473e-2e4c-43bf-aad2-71203789c2fe/oai
https://hdl.handle.net/11424/241111
https://avesis.aybu.edu.tr/publication/details/96b9473e-2e4c-43bf-aad2-71203789c2fe/oai
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/10525
https://avesis.uludag.edu.tr/publication/details/96b9473e-2e4c-43bf-aad2-71203789c2fe/oai -
3
Authors: et al.
Contributors: et al.
Source: Cancer Journal
Subject Terms: Male, B-cell, Lymphoma, Mantle-Cell, Treatment response, Lymphoma, B-Cell/drug therapy/pathology, Cancer growth, Multiple cycle treatment, 0302 clinical medicine, Phase 3 clinical trial, Prednisone/adverse effects/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Pathology, Treatment outcome, Aged, 80 and over, Antibodies, Monoclonal, Multicenter study, 3. Good health, Clinical trial, Antineoplastic agent, Randomized controlled trial, Vincristine, Nonhodgkin lymphoma, Drug dose reduction, Infection, Rituximab, Human, Cyclophosphamide/adverse effects/therapeutic use, Diarrhea, Lymphoma, B-Cell, Febrile neutropenia, Major clinical study, Lymphoma, T-Cell, Antibodies, Monoclonal/administration & dosage, Article, 03 medical and health sciences, Health Sciences, Vincristine/adverse effects/therapeutic use, Humans, Cyclophosphamide, Aged, Recombinant granulocyte colony stimulating factor, Leukopenia, Cardiotoxicity, Cancer combination chemotherapy, B cell lymphoma, Επιστήμες Υγείας, Comparative study, Vincristine sulfate, Ceop protocol 1, Lymphoma, Mantle-Cell/drug therapy/pathology, Lymphoma, Unclassified drug, T cell lymphoma, Antibodies, Monoclonal, Murine-Derived, T-cell, Controlled clinical trial, Nausea and vomiting, Deep vein thrombosis, Monoclonal, Lymphoma, T-Cell/drug therapy/pathology, Overall survival, Middle aged, Fatigue, Priority journal, Drug withdrawal, Lymphoma, Non-Hodgkin/*drug therapy/pathology, Lymphoma, Non-Hodgkin, Doseintensification, Anemia, Brain hemorrhage, Middle Aged, Anorexia, Female, Drug hypersensitivity, Monoclonal antibody, Adult, Neutropenia, Fever, Aggressive non-hodgkin lymphoma, Adolescent, Liver toxicity, Antibodies, Mucosa inflammation, Antineoplastic combined chemotherapy protocols, Neurotoxicity, Drug dose comparison, Ceop, Epirubicin, Non-hodgkin, Mantle cell lymphoma, Alopecia, Thrombocytopenia, Epirubicin/adverse effects/therapeutic use, Mantle-cell, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Prednisone, Controlled study
Access URL: https://pubmed.ncbi.nlm.nih.gov/17921732
https://www.ncbi.nlm.nih.gov/pubmed/17921732
https://europepmc.org/abstract/MED/17921732
http://olympias.lib.uoi.gr/jspui/handle/123456789/23225
https://pergamos.lib.uoa.gr/uoa/dl/object/3095456
https://pergamos.lib.uoa.gr/uoa/dl/object/2953205
https://pergamos.lib.uoa.gr/uoa/dl/object/2950958
https://gnosis.library.ucy.ac.cy/handle/7/41604 -
4
Authors: et al.
Source: Lupus. 15:371-379
Subject Terms: Adult, Male, Prednisolone - adverse effects - therapeutic use, Prednisolone, Infections, Kidney Function Tests, Mycophenolic Acid - adverse effects - analogs & derivatives - therapeutic use, Severity of Illness Index, 03 medical and health sciences, Immunosuppressive Agents - adverse effects - therapeutic use, 0302 clinical medicine, Activities of Daily Living, Amenorrhea - chemically induced, Humans, Amenorrhea, Cyclophosphamide, Fatigue, Retrospective Studies, Remission Induction, Alopecia, Middle Aged, Mycophenolic Acid, Patient Acceptance of Health Care, Lupus Nephritis, Lupus Nephritis - drug therapy - pathology - psychology, 3. Good health, Infection - chemically induced, Quality of Life, Fatigue - etiology - prevention & control, Drug Evaluation, Female, Alopecia - chemically induced, Cyclophosphamide - adverse effects - therapeutic use, Immunosuppressive Agents, Follow-Up Studies
Access URL: https://pubmed.ncbi.nlm.nih.gov/16830884
https://core.ac.uk/display/37908156
http://journals.sagepub.com/doi/10.1191/0961203306lu2307xx
https://lup.sagepub.com/content/15/6/371.full.pdf
http://hub.hku.hk/handle/10722/76918
https://www.ncbi.nlm.nih.gov/pubmed/16830884
https://lup.sagepub.com/content/15/6/371
http://hdl.handle.net/10722/76918 -
5
Authors: et al.
Source: Lupus. 15:380-383
Subject Terms: Prednisolone - adverse effects - therapeutic use, Arthroplasty, Replacement, Hip, Replacement, Fasciitis, Necrotizing - drug therapy - etiology - surgery, Scleroderma, Arthritis, Rheumatoid, Fishes - microbiology, Fatal Outcome, 0302 clinical medicine, Femur Head Necrosis, Diffuse - complications - drug therapy, Gram-Negative Bacterial Infections - drug therapy - etiology - surgery, Fasciitis, 2. Zero hunger, Fishes, Shock, Skin Transplantation, Middle Aged, Combined Modality Therapy, Anti-Bacterial Agents, 3. Good health, Anti-Bacterial Agents - therapeutic use, Rheumatoid - complications - drug therapy, Female, Aeromonas, Infection, Immunosuppressive Agents, Adult, Arthritis, Infectious - etiology, Immunocompromised hosts, Necrotizing - drug therapy - etiology - surgery, Arthroplasty, Femur Head Necrosis - chemically induced - surgery, Immunocompromised Host, 03 medical and health sciences, Immunosuppressive Agents - adverse effects - therapeutic use, Skin - injuries, Animals, Humans, Surgical Wound Infection - etiology, Fasciitis, Necrotizing, Disseminated Intravascular Coagulation - etiology, Cyclophosphamide, Arthritis, Infectious, β-haemolytic streptococcus, Hip, Lupus Erythematosus, Pseudomonas Infections - drug therapy - etiology - surgery, Arthritis, Immunocompromised hosts, β-haemolytic streptococcus, Infectious - etiology, Septic - etiology, Disseminated Intravascular Coagulation, Debridement, Systemic - complications - drug therapy, Arthritis, Rheumatoid - complications - drug therapy, Shock, Septic - etiology, Cyclophosphamide - adverse effects - therapeutic use, Gram-Negative Bacterial Infections, Lupus Erythematosus, Systemic - complications - drug therapy, Streptococcal Infections - drug therapy - etiology - surgery, Scleroderma, Diffuse - complications - drug therapy, Aeromonas - isolation & purification
Access URL: https://pubmed.ncbi.nlm.nih.gov/16830885
https://www.ncbi.nlm.nih.gov/pubmed/16830885
http://hub.hku.hk/handle/10722/78059
https://core.ac.uk/display/37908816
http://journals.sagepub.com/doi/abs/10.1191/0961203306lu2314cr
https://europepmc.org/article/MED/16830885
https://scholars.cityu.edu.hk/en/publications/necrotizing-fasciitis-in-rheumatic-diseases(5c745090-8bcd-4b26-bad3-70e881861162).html
http://hdl.handle.net/10722/78059 -
6
Authors: et al.
Source: Cancer Genetics and Cytogenetics. 141:79-82
Subject Terms: Chromosomes, Human, Pair 8 - genetics, Pulmonary Fibrosis, Pair 8 - genetics, Chromosomes, Fluorescence, Chromosome Banding, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Pulmonary Fibrosis - complications - drug therapy - genetics, Myelodysplastic Syndromes, Humans, Female, Cyclophosphamide - adverse effects - therapeutic use, Myelodysplastic Syndromes - chemically induced - complications - genetics, Cyclophosphamide, In Situ Hybridization, In Situ Hybridization, Fluorescence, Human, Aged, Chromosomes, Human, Pair 8
Access URL: https://pubmed.ncbi.nlm.nih.gov/12581903
https://pubmed.ncbi.nlm.nih.gov/12581903/
https://www.sciencedirect.com/science/article/pii/S0165460802006611
https://www.sciencedirect.com/science/article/pii/S0165460802006611#!
https://www.ncbi.nlm.nih.gov/pubmed/12581903
http://hub.hku.hk/handle/10722/78735
http://hdl.handle.net/10722/78735 -
7
Authors: et al.
Contributors: et al.
Source: European journal of haematology
Subject Terms: Survival rate, Lymphoma, Cnop, Cyclophosphamide/adverse effects/*therapeutic use, Granulocyte colony-stimulating factor, 0302 clinical medicine, Neutropenia/chemically induced, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, 80 and over, Treatment outcome, Middle aged, Drug safety, Priority journal, Aged, 80 and over, Alopecia/chemically induced, Lymphoma, Non-Hodgkin, Remission Induction, Middle Aged, Lymphoma, Non-Hodgkin/*drug therapy/mortality, 3. Good health, Clinical trial, Survival Rate, Treatment Outcome, Antineoplastic agent, Aggressive non-hodgkin's lymphoma, Vincristine, Granulocyte colony stimulating factor, Nonhodgkin lymphoma, Cancer chemotherapy, Prednisone/adverse effects/*therapeutic use, Human, Adult, Epirubicin/adverse effects/*therapeutic use, Neutropenia, Adolescent, Prednisolone, Febrile neutropenia, Major clinical study, Article, Cancer grading, 03 medical and health sciences, Granulocyte Colony-Stimulating Factor/therapeutic use, Mitoxantrone/adverse effects/*therapeutic use, Vincristine/adverse effects/*therapeutic use, Antineoplastic combined chemotherapy protocols, Humans, Ceop, Cyclophosphamide, Drug induced disease, Aged, Epirubicin, Non-hodgkin, Patient compliance, Alopecia, Prednisolone/adverse effects/*therapeutic use, Cancer survival, Cancer combination chemotherapy, Drug efficacy, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Remission induction, Prednisone, Mitoxantrone
-
8
Authors:
Source: Anticancer Res. 19(5C):4429-34
Subject Terms: Cancer and Oncology, Cancer och onkologi, Adult, Antineoplastic Combined Chemotherapy Protocols/adverse, effects/*therapeutic use, Breast Neoplasms/blood/*drug therapy/surgery, Chemotherapy, Adjuvant, Cyclophosphamide/adverse effects/therapeutic use, Dose-Response Relationship, Drug, Epirubicin/adverse effects/therapeutic use, Feasibility Studies, Female, Fluorouracil/adverse effects/therapeutic use, Granulocyte Colony-Stimulating Factor/adverse effects/*therapeutic use, Hemoglobins/analysis, Humans, Leukocyte Count, Liver Function Tests, Middle Aged, Neutropenia, Platelet Count
Access URL: https://gup.ub.gu.se/publication/45509
-
9
Authors:
Source: New England Journal of Medicine. 363:2072-2074
Subject Terms: Immunosuppressive Agents/*adverse effects/therapeutic use, Patient Selection, Remission Induction, therapy/mortality, Cyclophosphamide/adverse effects/*therapeutic use, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Monoclonal, Murine-Derived/*adverse effects/therapeutic use, Neoplasms/*chemically induced, 3. Good health, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug, Kidney Diseases/*drug therapy/mortality, Antibodies, Monoclonal, Murine-Derived, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Humans, Kidney Diseases, Treatment Failure, Rituximab, Cyclophosphamide, Immunosuppressive Agents
Access URL: https://pubmed.ncbi.nlm.nih.gov/21083399
https://pubmed.ncbi.nlm.nih.gov/21083400
https://pubmed.ncbi.nlm.nih.gov/21083398
https://pubmed.ncbi.nlm.nih.gov/21083401
https://pubmed.ncbi.nlm.nih.gov/21083399/
https://www.nejm.org/doi/pdf/10.1056/NEJMc1009101
https://europepmc.org/article/MED/21083400
https://www.ncbi.nlm.nih.gov/pubmed/21083400
http://olympias.lib.uoi.gr/jspui/handle/123456789/18535 -
10
Authors: Klevemark, P
Source: Sjukskötersketidningen. 15(2):37
-
11
Authors: et al.
Source: Journal Articles
Subject Terms: Adult, Antirheumatic Agents/adverse effects/ therapeutic use, Cyclophosphamide/adverse effects/ therapeutic use, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunoconjugates/adverse effects/ therapeutic use, Lupus Nephritis/ drug therapy, Male, Time Factors, Treatment Outcome, Medical Molecular Biology
File Description: application/pdf
Relation: https://academicworks.medicine.hofstra.edu/publications/2852; https://academicworks.medicine.hofstra.edu/context/publications/article/3853/viewcontent/ArthritisRheumatol2014v66p3096.pdf
-
12
Authors: Karassa, F. B.
Subject Terms: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug, therapy/mortality, Antibodies, Monoclonal, Murine-Derived/*adverse effects/therapeutic use, Cyclophosphamide/adverse effects/*therapeutic use, Humans, Immunosuppressive Agents/*adverse effects/therapeutic use, Kidney Diseases/*drug therapy/mortality, Neoplasms/*chemically induced
Availability: http://olympias.lib.uoi.gr/jspui/handle/123456789/18535
-
13
Authors: et al.
Subject Terms: Adolescent, Adult, Aged, 80 and over, Alopecia/chemically induced, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Cyclophosphamide/adverse effects/*therapeutic use, Epirubicin/adverse effects/*therapeutic use, Granulocyte Colony-Stimulating Factor/therapeutic use, Humans, Lymphoma, Non-Hodgkin/*drug therapy/mortality, Middle Aged, Mitoxantrone/adverse effects/*therapeutic use, Neutropenia/chemically induced, Prednisolone/adverse effects/*therapeutic use, Prednisone/adverse effects/*therapeutic use, Remission Induction, Survival Rate, Treatment Outcome, Vincristine/adverse effects/*therapeutic use
Availability: http://olympias.lib.uoi.gr/jspui/handle/123456789/20343
Nájsť tento článok vo Web of Science 
Full Text Finder